Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273175 | 0.80 | POLB (0.44) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL13529255 | 0.79 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2275411 | 0.78 | SMN1; SMN2 (0.44) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2276464 | 0.78 | LMNA (0.50) | CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL2360983 | 0.78 | CYP19A1 (0.47) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1860902 | 0.75 | CYP19A1 (0.55) | CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL2359438 | 0.74 | KMT2A (0.49) | CYP19A1 | |
| SCHEMBL31272114 | 0.74 | F2R (0.40) | — | |
| SCHEMBL17458995 | 0.72 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2LOXL2 | |
| SCHEMBL28170054 | 0.72 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288403-B2 | Heterocyclic gamma secretase modulators | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| CN-102209537-A | Heterocyclic gamma secretase modulators | HOFFMANN LA ROCHE | 2011-10-05 | — | — | CN | disclosed |
| EP-2355817-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010052199-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120874-A1 | HETEROCYCLIC GAMMA SECRETASE MODULATORS | BACE1, APH1A, APP | CYP19A1 3639/4885CYP11B1 2282/4885CYP11B2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.